Abstract
BACKGROUND: High-mobility group box 1 (HMGB1) is a key mediator of neuroinflammation and there are increased HMGB1 levels in laboratory animal models of epilepsy and human patients with epilepsy. OBJECTIVES: To determine serum HMGB1 levels in dogs with epilepsy. ANIMALS: Twenty-eight epileptic dogs, 12 dogs with nonepileptic brain diseases, and 26 healthy dogs. METHODS: In this case-control study, serum HMGB1 concentrations were estimated using the canine-specific enzyme-linked immunosorbent assay kit. Diagnosis of dogs with epilepsy was based on medical history, physical and neurological examination findings, laboratory test results, magnetic resonance image, and cerebrospinal fluid analysis. RESULTS: Serum HMGB1 levels were significantly higher in epileptic dogs (median = 0.41 ng/mL; range, 0.03-5.28) than in healthy dogs (median = 0.12 ng/mL; range, 0.02-1.45; P = .002). In contrast, serum HMGB1 levels of dogs with non-epileptic brain diseases (median = 0.19 ng/mL; range, 0.03-1.04) were not significantly increased compared to those of healthy dogs (P = .12). Regarding idiopathic epilepsy, dogs with an epilepsy course of >3 months showed a higher serum HMGB1 concentration (median = 0.87 ng/mL; range, 0.42-2.88) than those with that of ≤3 months (median = 0.26 ng/mL; range, 0.03-0.88; P = .02). CONCLUSIONS AND CLINICAL IMPORTANCE: Serum HMGB1 could be a biomarker of epilepsy.